Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AKRINOL vs SCLEROSOL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Not available; likely a combination product with antihistaminic and sympathomimetic actions.
SCLEROSOL (sodium tetradecyl sulfate) is a sclerosing agent that acts by irritating the intimal endothelium of blood vessels and causing inflammation, thrombosis, and fibrosis, leading to obliteration of the injected vein.
Allergic rhinitis,Nasal congestion
Treatment of uncomplicated spider veins (telangiectasias) and reticular veins of the lower extremities,Treatment of small varicose veins
Adults: 100 mg orally twice daily.
0.5-5 m L of 5% solution administered by intrapleural injection once daily for up to 3 days.
3-4 hours (prolonged to 8-12 hours in renal impairment; no dose adjustment typically needed unless Cr Cl <30 m L/min).
60-90 minutes (clinical context: rapid elimination requires multiple daily dosing for maintenance of effect)
Not available; components may be metabolized via hepatic CYP enzymes.
Sodium tetradecyl sulfate is a small molecule that is not significantly metabolized; it is eliminated primarily via renal excretion.
Primarily renal (80-90% as unchanged drug via glomerular filtration and tubular secretion); minor biliary/fecal (5-10%).
Primarily renal (80-90% unchanged), minimal biliary/fecal (5-10%)
99.5% (primarily to albumin; also to α1-acid glycoprotein).
20-30% (primarily to albumin)
0.10-0.17 L/kg (low, indicating limited extravascular distribution; primarily in central compartment).
0.3-0.5 L/kg (clinical meaning: moderate distribution, mainly in extracellular fluid)
Oral: 3-5% (extensive first-pass metabolism); IV: 100%.
Oral: 10-20% (first-pass effect); subcutaneous: 70-80%; intramuscular: 75-85%; intravenous: 100%
GFR 30-59 m L/min: 50 mg daily; GFR <30 m L/min: 50 mg every other day.
No specific dose adjustment required; use with caution in severe renal impairment.
Child-Pugh A: 100 mg twice daily; Child-Pugh B: 50 mg twice daily; Child-Pugh C: 50 mg daily.
No specific dose adjustment required for Child-Pugh A or B; avoid in Child-Pugh C due to risk of toxicity.
Children (1-12 years): 2 mg/kg orally twice daily, max 100 mg/dose.
Not recommended for pediatric use due to lack of safety and efficacy data.
Adults >65 years: initiate at 50 mg twice daily, titrate to 100 mg twice daily as tolerated.
No specific dose adjustment; monitor for pleural irritation and systemic effects due to increased sensitivity.
None
There is no FDA black box warning for SCLEROSOL.
Use with caution in patients with hypertension,Avoid in patients with severe coronary artery disease
Anaphylactic shock and allergic reactions,Arterial injection causing tissue necrosis,Deep vein thrombosis and pulmonary embolism,Intra-arterial injection leading to severe ischemia,Risk of anaphylaxis in patients with multiple allergies
Hypersensitivity to any component,Severe hypertension,Concomitant use with MAO inhibitors
Known hypersensitivity to sodium tetradecyl sulfate,Acute thromboembolic disease,Severe peripheral arterial disease,Incompetent perforating veins without treatment of underlying reflux,Uncontrolled systemic disease (e.g., diabetes, hyperthyroidism),Local infection at the injection site,Bedridden patients
No known food interactions with topical naftifine. No dietary restrictions required.
No known food interactions. Maintain adequate hydration. Avoid alcohol for 24 hours post-treatment to minimize vasodilation.
FDA Pregnancy Category D. First trimester: risk of CNS defects and spontaneous abortion. Second/third trimester: risk of premature closure of ductus arteriosus, oligohydramnios, renal dysfunction, necrotizing enterocolitis, periventricular hemorrhage, and pulmonary hypertension.
FDA Pregnancy Category C. Sclerosol (talc) is not absorbed systemically when used intrapleurally; however, inadvertent intravenous administration or systemic absorption may occur. Animal reproduction studies have not been conducted. Inadvertent maternal exposure could theoretically cause fetal harm. Use only if clearly needed during pregnancy; avoid during first trimester if possible.
Contraindicated during breastfeeding. M/P ratio not determined due to contraindication. Excreted into breast milk; potential for serious adverse effects in infant.
No data on excretion into breast milk. Talc is not absorbed systemically when used intrapleurally, but trace amounts may enter milk. Due to lack of studies, caution is advised. The milk-to-plasma ratio is unknown. Consider discontinuing breastfeeding or alternative agents.
No established safe dose. Generally contraindicated during pregnancy. If used, lowest effective dose and shortest duration. Avoid after 20 weeks gestation.
No pharmacokinetic changes expected as systemic absorption is negligible. Standard intrapleural dosing (e.g., 2-10 g in 50-250 m L saline) may be used, but consider gestation-related pleural space changes. No dose adjustment recommended, but use lowest effective dose to minimize complications.
AKRINOL is a topical antifungal (naftifine) that inhibits squalene epoxidase, effective against dermatophytes. Apply once daily for 2-4 weeks. Avoid occlusive dressings. Monitor for local irritation or allergic contact dermatitis.
SCLEROSOL (sodium tetradecyl sulfate) is a sclerosing agent used for varicose veins and telangiectasias. Avoid extravasation; tissue necrosis may occur. Use caution in patients with thrombophlebitis or hypercoagulable states. Max dose per session: 10 m L of 3% solution. Contraindicated in pregnancy and known allergy to the drug.
Apply a thin layer to the affected area once daily, usually for 2 to 4 weeks.,Wash hands before and after application unless treating the hands.,Do not cover the treated area with bandages or wraps unless directed.,Avoid contact with eyes, nose, mouth, or broken skin. If contact occurs, rinse with water.,Notify your doctor if condition worsens, does not improve within 4 weeks, or if severe irritation or allergic reaction develops.
You may experience a burning sensation at the injection site that lasts a few minutes.,Avoid strenuous activity and prolonged standing for 24-48 hours after treatment.,Wear compression stockings as directed to improve outcomes and reduce side effects.,Report any signs of infection, severe pain, or leg swelling to your doctor immediately.,Multiple sessions may be needed for complete vein closure.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AKRINOL vs SCLEROSOL, answered by our medical review team.
AKRINOL is a Topical Retinoid that works by Not available; likely a combination product with antihistaminic and sympathomimetic actions.. SCLEROSOL is a Sclerosing Agent that works by SCLEROSOL (sodium tetradecyl sulfate) is a sclerosing agent that acts by irritating the intimal endothelium of blood vessels and causing inflammation, thrombosis, and fibrosis, leading to obliteration of the injected vein.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AKRINOL and SCLEROSOL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AKRINOL is: Adults: 100 mg orally twice daily.. The standard adult dose of SCLEROSOL is: 0.5-5 m L of 5% solution administered by intrapleural injection once daily for up to 3 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AKRINOL and SCLEROSOL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AKRINOL is classified as Category C. FDA Pregnancy Category D. First trimester: risk of CNS defects and spontaneous abortion. Second/third trimester: risk of premature closure of ductus arteriosus, oligohydramnios, re. SCLEROSOL is classified as Category C. FDA Pregnancy Category C. Sclerosol (talc) is not absorbed systemically when used intrapleurally; however, inadvertent intravenous administration or systemic absorption may occur. . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.